[Alpha Biz= Reporter Kim Jisun] South Korean private equity firm MBK Partners will acquire Japan's well-known pharmaceutical company Alinamin Pharmaceutical for approximately 2.9 trillion KRW.
According to the financial investment industry on the 2nd, MBK Partners is set to sign a stock purchase agreement with U.S. private equity firm Blackstone on the 3rd for the acquisition of Alinamin Pharmaceutical at the stated amount.
Alinamin Pharmaceutical originated as Takeda Consumer Healthcare, a subsidiary of Japan’s Takeda Pharmaceutical Company. It was acquired by Blackstone in 2021 and subsequently renamed.
Alinamin Pharmaceutical is well-known for its vitamin and fatigue recovery products.
AlphaBIZ Kim Jisun(stockmk2020@alphabiz.co.kr)
